Chief Executive Officer
Marc Beer is the Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the U.S. Food and Drug Administration in December 2012...
Read more & view related media
Will Andrews, MD, FACP
Senior Vice President, Business Development
William “Will” Andrews was appointed Senior Vice President of Business Development in May 2014. Dr. Andrews assumed the business development role after having spent two years as Vice President of Medical Affairs for Aegerion, starting and building the Medical Affairs function and overseeing medical affairs activities for the launch of JUXTAPID® in the United States, Canada, Latin America, and Asia. Prior to joining Aegerion in 2012, Dr. Andrews held Medical Affairs leadership roles with Santhera Pharmaceuticals and Sepracor. Before that, he was Medical Director at ClinQuest, where he worked on the Clinical Development of multiple innovative therapies and programs. Prior to joining the biopharmaceutical industry over 15 years ago, Dr. Andrews practiced Internal Medicine in Boston at Harvard Vanguard Medical Associates and Brigham and Women’s Hospital. He has also served as Clinical Instructor of Internal Medicine at Harvard Medical School and Attending Physician of Internal Medicine at Brigham and Women’s Hospital. Dr. Andrews received his Doctor of Medicine degree from Yale University School of Medicine, and his Bachelor of Arts degree in Biology from Harvard University.
Chief Regulatory Officer
Martha Carter was appointed Chief Regulatory Officer of Aegerion in February 2011, bringing over 30 years of regulatory affairs experience in prescription and over-the-counter drugs, biologics, biotechnology products, and medical devices. Prior to joining Aegerion, Martha was Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. where she was responsible for the company's worldwide regulatory and quality functions. Prior to this role, she was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to that, Martha was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. In this role, she led the company's regulatory and quality control functions for both commercial and investigational drug products. Martha is a Fellow of the Regulatory Affairs Professionals Society, and is a past President and Chairman of the Board. She is also a former member of the Editorial Advisory Board for Applied Clinical Trials and BioPharm. Martha holds a B.A. in Biology from Northeastern University.
Anne Marie Cook
Senior Vice President, General Counsel and Secretary
Anne Marie Cook was appointed Senior Vice President, General Counsel and Secretary in December 2011. Ms. Cook was most recently a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate). There she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property licenses. She also provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, Ms. Cook was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc. Prior to that, she was Vice President, Chief Corporate Counsel, at Biogen Idec Inc.
Chief Financial Officer
Mark Fitzpatrick was appointed Chief Financial Officer in April of 2011. He brings over 15 years of financial management experience in both public and private companies. He was most recently Vice President, Chief Financial Officer and Assistant Secretary at Proteon Therapeutics, Inc. Prior to his role at Proteon, Mr. Fitzpatrick was Vice President and Chief Financial Officer, Treasurer and Assistant Secretary with RenaMed Biologics, Inc. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. He previously was a senior auditor with Arthur Andersen & Co. Mr. Fitzpatrick earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987, and holds a B.S. in Accounting from Boston College.
Chief Operating Officer
Craig Fraser was appointed Chief Operating Officer in July 2014. Prior to that, he was President, U.S. Commercial and Global Manufacturing and Supply Chain for Aegerion since September 2012. Before joining Aegerion, Mr. Fraser was Vice President, Global Disease Areas at Pfizer Inc. responsible for the commercial development and global marketing for the Specialty Cardiovascular, Anti-Bacterial, Anti-Fungal, Gastrointestinal and Anti-Viral disease areas, where he managed a portfolio of six products totaling over three billion dollars in revenue and multiple new products in development. He was charged with establishing the company's future specialty cardiovascular business including commercial inputs for the rare disease lipid market. Prior to Pfizer, Mr. Fraser was Vice President and Global Business Manager at Wyeth, where he led the institutional/infectious disease business. Before that, Mr. Fraser held several commercial positions at Johnson & Johnson, most recently as Vice President, Commercial Operations and Oncology Sales and Marketing. Previously, he was Gastroenterology Franchise lead as well as National Sales Director of the Immunology and Cardiovascular business units at Centocor, a start-up biotech and diagnostic company focused on monoclonal antibody-based technology.
Mark Sumeray, MD, MS, FRCS
Chief Medical Officer
Dr. Sumeray brings development, regulatory and medical affairs experience with cardiovascular drugs such as Plavix®, apixaban, Avapro®/Avalide®, and Angiomax® to Aegerion. Dr. Sumeray was most recently Vice President Cardiovascular/Metabolics U.S. Medical, at Bristol-Myers Squibb. In this role, he was responsible for U.S. medical strategy for the CV and metabolics medical strategy teams, including implementation across the medical affairs function working collaboratively with marketing, sales, global clinical research and health outcomes. Prior to this role, Dr. Sumeray held several positions of increasing responsibility within The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President Medical Business Development, and Vice President Clinical Development and Head of Medical Science. Prior to that, Dr. Sumeray was worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson.
Senior Vice President, Human Resources
Mary Weger was appointed Senior Vice President, Human Resources in December, 2011. Mary brings over 30 years of Human Resource experience, eleven of which has been within the biopharmaceutical industry. Prior to joining Aegerion, Mary was Senior Vice President, Global Clinical Development Strategy & Effectiveness at Celgene Corporation. Prior to this appointment, she held the position of Senior Vice President, Global Human Resources at Celgene where she played an instrumental role in helping to build Celgene globally from a company with 150+ employees to a world-wide organization with revenue of over 4 billion and operations in over 30 countries. Prior to Celgene, Mary held positions of increasing responsibility at Kraft Foods Nabisco. She received her Masters certificate and Black Belt in Six Sigma in 2011 from Villanova University and also possesses a MA in Human Resource Management as well as having completed the Executive Human Resources program at Michigan University. Mary currently serves on the Board of Family Promise, a non-profit organization addressing the needs of homeless families.